Origin and functional consequences of the complex I defect in Parkinson's disease

Annals of Neurology

Volumn 40, Issue 4, 1996, Pages 663-671

  Swerdlow, Russell H ^a   Parks, Janice K ^a   Miller, Scott W ^b   Tuttle, Jeremy B ^a   Trimmer, Patricia A ^a   Sheehan, Jason P ^a   Bennett Jr , James P ^a   Davis, Robert E ^b   Parker Jr , W Davis ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b Migenix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CELL NUCLEUS DNA; MITOCHONDRIAL DNA; OXYGEN RADICAL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HYBRID CELL; MALE; NERVE DEGENERATION; NEUROBLASTOMA CELL; PARKINSON DISEASE; PRIORITY JOURNAL; RESPIRATORY CHAIN;

1-METHYL-4-PHENYLPYRIDINIUM; AGED; APOPTOSIS; CELL DEATH; DNA, MITOCHONDRIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NAD; NAD(P)H DEHYDROGENASE (QUINONE); PARKINSON DISEASE; POINT MUTATION;

EID: 0029908226     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400417     Document Type: Article

References (53)

1. de Rijk MC, Breteler MMB, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45:2143-2146
2. Ward CD, Duvoisin RC, Ince SE, et al. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983;33:815-824
3. Marsden CD. Parkinson's disease in twins. J Neurol Neurosurg Psychiatry 1987;50:105-106
4. Martilla RJ, Kaprio J, Koskenvuo M, et al. Parkinson's disease in a nationwide twin cohort. Neurology 1988;38:1217-1219
5. Golbe LI. The genetics of Parkinson's disease: a reconsideration. Neurology 1990;40(suppl 3):7-14
6. Langston JW, Ballard PA, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980
7. Nicklas WJ, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 1985;36:2503-2508
8. Ramsay RR, Salach JI, Dadgar J, Singer TP. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem Biophys Res Commun 1986;135:269-275
9. Parker WD, Boyson SJ, Parks JK. Electron transport chain abnormalities in idiopathic Parkinson's disease. Ann Neurol 1989;26:719-723
10. Haas RH, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37:714-722
11. Benecke R, Strumper P, Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 1993;116:1451-1455
12. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm 1992;41:27-34
13. Krige D, Carroll MT, Cooper JM, et al. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 1992;32:782-788
14. Schapira AHV, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-827
15. Janetzky B, Hauck S, Moussa BH, et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett 1994;169:126-128
16. Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989;163:1450-1455
17. Shoffner JM, Watts RL, Juncos JL, et al. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 1991;30:332-339
18. Bindoff LA, Birch-Machin MA, Cartlidge NE, et al. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci 1991;104:203-208
19. Blin O, Desnuelle C, Rascol O, et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J Neurol Sci 1994;125:95-101
20. Nakagawa-Hattori Y, Yoshino H, Kondo T, et al. Is Parkinson's disease a mitochondrial disorder? J Neurol Sci 1992;107: 22-33
21. Cardellach F, Marti MJ, Fernandez-Sola J, et al. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 1993;43:2258-2262
22. Mytilineau C, Werner P, Molinari S, et al. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease. J Neural Transm 1994;8:223-228
23. Nichols DG. Bioenergetics: an introduction to the chemiosmotic theory. Orlando, FL: Academic, 1982
24. Arizmendi JM, Skebel JM, Runswick MJ, et al. Complementary DNA sequences of two 14.5 kDa subunits of NADH: ubiquinone oxidoreductase from bovine heart mitochondria. Complementation of the primary structure of the complex? FEBS Lett 1992;313:80-84
25. Parker WD. Sporadic neurologic disease and the electron transport chain: a hypothesis. In: Pascuzzi RM, ed. Proceedings of the 1989 scientific meeting of the American Society for Neurological Investigation: new developments in neuromuscular disease. Bloomington: Indiana University Printing Services, 1990: 59-64
26. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442
27. King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989;246:500-503
28. lys mutation causing myoclonic epilepsy and ragged red fibers. J Hum Genet 1994;54: 966-974
29. Ratinaud MH, Leprat P, Julien R. In situ flow cytometric analysis of nonyl acridine orange-stained mitochondria from splenocytes. Cytometry 1988;9:206-212
30. Parker WD, Parks JK, Filley CM, Kleinschmidt-DeMasters BK. Electron transport chain defects in Alzheimer's disease. Neurology 1994;44:1090-1096
31. Rosenkranz AR, Schmaldienst S, Stuhlmeier KM, et al. A microplate assay for the detection of oxidative products using 2',7'-dichlorofluorescin-diacetate. J Immunol Methods 1992; 156:39-45
32. Desjardins P, Frost E, Morais R. Ethidium bromide-induced loss of mitochondrial DNA from primary chicken embryo fibroblasts. Mol Cell Biol 1985;5:1163-1169
33. Desjardins P, de Muys JM, Morais R. An established avian fibroblast cell line without mitochondrial DNA. Somat Cell Mol Genet 1986;12:133-139
34. Morais R, Desjardins P, Turmel C, Zinkewich-Peotti K. Development and characterization of continuous avian cell lines depleted of mitochondrial DNA. In Vitro Cell Dev Biol 1988; 24:649-658
35. Gregoire M, Morais R, Quilliam MA, Gravel D. On auxotrophy for pyrimidines of respiration-deficient chick embryo cells. Eur J Biochem 1984;142:49-55
36. Johns DR. Mitochondrial DNA and disease. N Engl J Med 1995;333:638-644
37. Zensen R, Heisman H, Schneider R, et al. De novo synthesis and desaturation of fatty acids at the mitochondrial acyl-carrier protein, a subunit of NADH:ubiquinone oxidoreductase in Neurospora crassa. FEBS Lett 1992;310:179-181
38. Ikebe S, Tanaka T, Ozawa T. Point mutations of mitochondrial genome in Parkinson's disease. Mol Brain Res 1995;28: 281-295
39. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40:32-37
40. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative diseases? Ann Neurol 1992;31:119-130
41. Greenland LJS, Deckwerth TL, Johnson EM. Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron 1995;14:303-315
42. Zang LY, Misra HP. Generation of reactive oxygen species during monoamine oxidase-catalyzed oxidation of the neurotoxicant, 1-methyl-4-1,2,3,6-tetrahydropyridine. J Biol Chem 1993;268:16504-16512
43. Partridge R, Parks JK, Johnson K, et al. Spin trapping of azidyl radical in azide-inhibited rat brain mitochondria. Arch Biochem Biophys 1994;310:210-217
44. Turski L, Bressler R, Rettig KJ, et al. Protection of substantia nigra from MPP+ neurotoxicity by n-methyl-D-aspartate antagonists. Nature 1991;349:414-418
45. Smith TS, Swerdlow RH, Parker WD Jr, Bennett JP Jr. Reduction of MPP(+)-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. Neuroreport 1994;5:2598-2600
46. Koller WC, Langsten JW, Hubble JP, et al. Does a long preclinical period occur in Parkinson's disease? Neurology 1991; 41(suppl 2):8-13
47. Shoubridge EA, Karpati G, Hastings EM. Deletion mutants are functionally dominant over wild-type mitochondrial genomes in skeletal muscle fiber segments in mitochondrial disease. Cell 1990;62:43-49
48. Hayashi JI, Ohta S, Kikuchi A, et al. Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction. Proc Natl Acad Sci USA 1991;88:10614-10618
49. Wiseman A, Attardi G. Reversible tenfold reduction in mitochondria DNA content of human cells treated with ethidium bromide. Mol Gen Genet 1978;167:51-63
50. Di Monte DA. Mitochondrial DNA and Parkinson's disease. Neurology 1991;41(suppl 2):38-42
51. Parker WD, Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990;40:1302-1303
52. Kish SJ, Bergeron C, Rajput A, et al. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 1992;59:113-114
53. Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 1994;63:2179-2184